The causal therapy of Aspirin (ASA)-exacerbated respiratory disease (AERD) consists
of the repetitive administration of ASA (ASA desensitization), which aims to normalize
the arachidonic acid (AA) metabolism and improves disease progression.
The functional eicosanoid test investigates the individual metabolism in vitro.
It‘s unknown, which metabolic parameters correlate with the clinical symptoms for
follow-up under ASA desensitization and allow conclusions to be drawn on the success
of treatment.
This prospective study correlates metabolic parameters and clinical symptoms to identify
appropriate course parameters.
Methods In 16 AERD patients, the metabolic parameters AIT, PG, LT, R, S and N were assessed
under ASS desensitization using a functional eicosanoid test and were correlated with
the clinical course of the disease and the quality of life of the patients.
Results The improvement of the quality of life and the ability to smell under ASA desensitization
correlates with the normalization of the S-value (p = 0.001, p = 0.008). The S-value
correlates with the endoscopic polyp score (p = 0.024).
Treatment discontinuations show poorer quality of life, endoscopically poorer nasal
findings and significantly lower normalizations of the AIT, S values (p = 0.026, p
= 0.024).
Conclusion This prospective study describes for the first time a positive correlation of specific
objective metabolic parameters under ASA desensitization and clinical disease progression.
The monitoring of the S value allows to control the course of the AERD, to adapt the
ASA dose individually and thus to perform it more effectively and with fewer side-effects.
The AIT value is ideally suited for confirming the diagnosis of AERD
Poster-PDF
A-1530.pdf
HELIOS Klinik Wiesbaden
